“a nonsignificant trend”

A nonsignificant trend towards lower grade ≥3 complications in wedge vs. segmentectomy was seen in the CALGB study (11% vs. 19%, P=0.13) ( 9 ).

Progression-Free Survival Patients with high pathological necrosis (≥80%) showed a nonsignificant trend toward improved PFS compared with those with poor necrosis ( p = 0.13).

Whites exhibited a nonsignificant trend towards higher CMV seropositivity rates within these clusters as well (54% vs 44%; OR = 1.51; 95% CI, .85–2.70; P = .13).

Thus, we focused on those two measures to assess if there were any association between treatment and these markers There were no statistically significant differences in the SDI or ratio of F:B in the two treatment groups, although there was a nonsignificant trend towards higher F:B ratio in patients treated with CT (p=0.13, Mann-Whitney) ( Figure 3 ).

78%, p < .01), but among those who asked for questions, there was a nonsignificant trend towards greater use of the preferred open-ended method in the workshop group (25% vs. 15%, p = .13).

For all eligible patients ( n = 94), there was a nonsignificant trend to an increased risk in mortality in the etomidate group (adjusted OR: 4.8, 95% CI: 0.6–35.9, P = 0.13).

Specifically, whereas the home-based condition had a nonsignificant trend over the follow-up period (unstandardized β slope 2 intercept = 0.35, 95% CI, 0.09 to 0.79; P = .13), representing a return to near-baseline levels, the clinic-condition slope was significantly smaller (unstandardized β s lope2 = −0.44; 95% CI, −0.81 to −0.06, P = .02) in Table 2 .

While this represented a nonsignificant trend toward lower risk of major events associated with CVD by 9% (relative risk [RR]: 0.91, 95% confidence interval [CI]: 0.80–1.03; P = 0.13) with aspirin in the overall group, analysis by age indicated that aspirin significantly reduced major events in women aged ≥ 65 years (RR: 0.74, 95% CI: 0.59–0.92] in women aged ≥ 65 years vs (RR: 1.01, 95% CI: 0.81–1.26 in women aged 45–54 years).

Among nonresponders, a nonsignificant trend toward fewer epithelial cells ( P = .13) more frequently expressing HLA-DR ( P = .16) in the biopsies of vedolizumab recipients than control individuals suggests that the degree of colonic inflammation may differ between these 2 subgroups, with control individuals being slightly less inflamed ( Supplementary Figure 2E , F ).

After repeating the analyses in female subjects alone, the depletion type-by-diagnosis interaction in the left anterior PFC was reduced to a nonsignificant trend ( P =0.13); the depletion type-by-diagnosis interaction in the right anteromedial PFC ( P =0.08) and the right subgenual PFC ( P =0.06) and the effect of depletion type on the left ventrolateral PFC ( P =0.06) remained as trend effects.

The meta-analysis showed a nonsignificant trend favoring the intervention group (OR 0.55, 95% CI 0.25-1.19; P =.13; Figure 4 [ 27 , 28 , 35 , 40 ]; Multimedia Appendix 3 ).

The comparison between days 0 and 4 only showed a nonsignificant trend in the same analysis in favor of the control group (TLR3, p = 0.13; TLR7, p = 0.06; and TLR8, p = 0.13).

that examined the role of postoperative RT in mucosal melanoma of the head and neck, adjuvant RT versus surgery alone demonstrated a nonsignificant trend toward a lower rate of locoregional recurrence (p=0.13) ( 14 ).

There was a nonsignificant trend toward higher ORR in patients receiving CART or TCE-based salvage therapy compared to others (55% vs. 32%; P = 0.13).

VMI Improved in the Estradiol Treatment Group There was a nonsignificant trend toward improvement in the clinical vaginal atrophy score in the estradiol group ( P = .13) but no change in the no treatment group between baseline and 12-week ( Figure 2 B ).

When the modified percent score (MPS) was assessed as a continuous scale, we found a nonsignificant trend of higher MPS in patients with PFS-6 ( p = 0.13, Supplemental Table 6 ).

AF length definition (undefined or shorter than 30 s versus longer or equal to 30 s) explained 5.1% of the heterogeneity between studies with a nonsignificant trend towards higher detection yield in studies defining AF for a duration of at least 30 s (3.5% versus 6.1%, P =0.13).

A shorter scene time was associated with ROSC on arrival at the emergency department ( P < 0.001) and a nonsignificant trend for improved survival ( P = 0.13).

CT infection showed a nonsignificant trend toward higher intrapartum fever (12.5% vs 3.5%; P = 0.130).

Among these patients, a nonsignificant trend was noted toward increased post-code survival after RRT implementation (22.5% before implementation versus 41.4% after implementation; P = 0.13).

The mortality in patients with high BAL CMV viral load (>2.52 log copies/mL, 6/32 [18%]) showed a nonsignificant trend to be higher than in those with low CMV viral load (2/44 [5%], P = .13).

Concurrent with dominance of the Delta variant in July 2021, logistic regression revealed a nonsignificant trend toward increased viral load, that is, Ct values below the median (odds ratio = 1.41, 95% CI = 0.90–2.20, p = 0.13), compared with previous months.

Though there was a nominal SNP × metformin interaction in the fully adjusted model ( P = 0.04), the observed trend was in the opposite direction from the expected prevention effect; the C allele conferred no detectable advantage on metformin recipients in diabetes prevention but was associated with a nonsignificant trend toward increased risk of diabetes (HR per copy of the C allele 1.17 [0.96–1.42], P = 0.13).

There was a nonsignificant trend toward fewer patients seen for rhinoconjunctivitis/rhinosinusitis (29.4% vs 32.6%; P = .13).

There was a nonsignificant trend toward worse disability at 9 months in the INH-R category (cumulative OR, 1.44 [95% CI, .90–2.32], P = .13).